Search Results 91-100 of 15686 for B%20cell%20lymphomas

  1. Follow-up Letters for Subjects in the IRB# 13-001285 "Mayo Clinic Experience with Subjects Diagnosed with Diffuse Large B-cell Lymphoma (DLBCL)" Study

    Follow-up Letters for Subjects in the IRB# 13-001285 "Mayo Clinic Experience with Subjects Diagnosed with Diffuse Large B-cell Lymphoma (DLBCL)" Study. Print ...

  2. FT819 in Subjects With B-cell Malignancies - Mayo Clinic

    The purpose of this study is to assess the safety, tolerability, and clinical activity of FT819 in r/r B-cell malignancies, including the effect of a step- ...

  3. Mayo Clinic Comprehensive Cancer Center — Research

    Giving paclitaxel albumin-stabilized nanoparticle formulation and rituximab may work better in treating patients with B-cell non-Hodgkin lymphoma. Digital ...

  4. Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma - Mayo Clinic

    Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, ...

  5. Lymphoma - Doctors and departments - Mayo Clinic

    Developing the first genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non-Hodgkin ...

  6. Recent findings and future directions in non-Hodgkin's lymphoma therapy - Mayo Clinic

    Ansell's lymphoma research program, which focuses on the TME and B cell cancer biology, has produced over 450 journal articles, including the 2021 paper in JCO ...

  7. Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia - Mayo Clinic

    This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute ...

  8. Hairy cell leukemia - Symptoms and causes - Mayo Clinic

    The cells don't look like healthy B cells . Instead, they've undergone changes to become leukemia cells. The leukemia cells look "hairy" under a microscope.

  9. An Open-label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma - Mayo Clinic

    Other B-NHL cohort: Patients with B-NHL other than FL grade 1-3a, DLBCL, MCL, or MZL) that has relapsed or is refractory to at least 2 prior lines of ...

  10. Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma - Mayo Clinic

    Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin ...